
Albireo Pharma ALBO
Quartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma Betriebsaufwand 2011-2025 | ALBO
Betriebsaufwand Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 163 M | 105 M | 70.7 M | 50.6 M | 24.6 M | 14 M | 19.8 M | 19.3 M | 20.6 M | 19.3 M | 23.2 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 163 M | 14 M | 48.1 M |
Betriebsaufwand Vierteljährlich Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 42.4 M | 35.5 M | 41.7 M | - | 29.2 M | 20.1 M | 31.1 M | - | 22 M | 16.5 M | 15.9 M | - | 12.9 M | 11.1 M | 11.8 M | - | 6.53 M | 6.61 M | 6.1 M | - | 3.47 M | 6.03 M | 2.75 M | 3.23 M | 16.3 M | 6.58 M | 4.53 M | 5.24 M | 15.6 M | 4.75 M | 5.24 M | 5.04 M | 16.2 M | 5.22 M | 5.04 M | 5.91 M | 13.6 M | 4.73 M | 5.91 M | 4.37 M | 18.6 M | 5.32 M | 4.37 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 42.4 M | 2.75 M | 12.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.79 | 2.35 % | $ 795 M | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.04 | 4.83 % | $ 235 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 1.17 | 4.46 % | $ 6.38 M | ||
|
Aptevo Therapeutics
APVO
|
-31.8 M | $ 0.93 | -8.81 % | $ 257 K | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 212.81 | 1.71 % | $ 5 B | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Cerevel Therapeutics Holdings
CERE
|
447 M | - | - | $ 7.29 B | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.1 | 0.16 % | $ 7.46 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
BioVie
BIVI
|
18.1 M | $ 1.27 | -3.05 % | $ 1.88 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Celsion Corporation
CLSN
|
19.1 M | - | -6.63 % | $ 13.9 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 95.03 | 0.95 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.81 | 1.36 % | $ 1.3 B | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 9.48 | 0.96 % | $ 139 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.18 | -25.03 % | $ 392 M | ||
|
Cortexyme
CRTX
|
34.6 M | - | -1.05 % | $ 67.1 M | ||
|
Catalyst Biosciences
CBIO
|
176 M | $ 12.37 | 2.06 % | $ 814 M | ||
|
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
1.18 B | $ 591.15 | 0.02 % | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.53 | -0.39 % | $ 15.9 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | $ 92.45 | 0.34 % | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 26.83 | 0.94 % | $ 1.73 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 9.0 | -1.32 % | $ 1.48 B |